PDAC and NSCLC patients show a worse prognosis when expressing high AXL‐GAS6‐ENAH gene expression compared with the combined expression of AXL and GAS6 and indicate the relevance of hMENA as both a prognostic marker and a potential therapeutic target. The gene discussed is GAS6; the disease is non-small cell lung carcinoma.